My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 10

Managing RET Inhibitor Treatment-Related Adverse Events

,

Panelists discuss the common adverse effects for patients receiving selpercatinib or pralsetinib, strategies for managing these effects, and whether differences in the safety profiles of these drugs influence treatment choices for RET fusion–positive non–small cell lung cancer.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
EP. 6: Initial Approach to Management of RET-Positive NSCLC
EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC
EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
Now Viewing
EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events
  1. Dr Wakelee to Dr Sands: What adverse effects are common for patients receiving selpercatinib or pralsetinib?
  2. How do you manage these adverse effects?
  3. Are there any differences in safety profiles of these drugs that influence your treatment choice?
  4. LIBRETTO-431 Trial
  5. ARROW Trial
  6. ARROW Trial Update Annals of Oncology, 2022
  7. Dr Wakelee to Dr Sands: In what situations do you consider dose modifications of RET inhibitors? How often do you find this necessary in your practice?

Related Content:

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC Video SeriesInsights
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL
Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma